Aglamis, E.Tasdemir, C.Ceylan, C.2024-08-042024-08-0420130021-1265https://doi.org/10.1007/s11845-013-0914-1https://hdl.handle.net/11616/96118It has been known that the National Institutes of Health category IV (NIH-IV) prostatitis increases the serum total prostate-specific antigen (tPSA) in patients with benign prostatic hyperplasia. However, the effect of NIH-IV prostatitis on tPSA levels, which are used for staging prostate cancer (PCa) in patients with PCa, has not been previously investigated. To evaluate the effect of NIH-IV prostatitis on the tPSA which is used for staging PCa in patients with newly diagnosed PCa. A total of 198 patients in whom PCa was detected were included in the study. Group 1 included patients with only PCa, while Group 2 included patients with prostatitis and PCa. The tPSA levels of patients in Groups 1 and 2 were compared. A total of 120 (61 %) PCa (Group 1) and 78 (39 %) PCa + NIH-IV prostatitis (Group 2) patients were identified. The tPSA levels of 70 (58 %) patients in Group 1 and 22 (28 %) patients in Group 2 were at the interval of < 20 ng/ml (the mean levels of tPSA: 11.8 +/- A 4.5 and 14.1 +/- A 3.3, respectively). The tPSA levels of 50 (42 %) patients in Group 1 and 56 (72 %) patients in Group 2 were within the range of a parts per thousand yen20 ng/ml (the mean levels of tPSA: 39.9 +/- A 31.0 and 47.0 +/- A 29.2, respectively). Within both the < 20 ng/ml range and a parts per thousand yen20 ng/ml range, the mean tPSA value in Group 2 was found to be significantly higher than that of Group 1 (p = 0.03 and 0.01, respectively). The existence of NIH-IV prostatitis together with cancer in patients with PCa significantly increases the tPSA level which is used in staging the PCa.eninfo:eu-repo/semantics/closedAccessProstate cancerProstate-specific antigenProstatitisStageTreatmentBiopsyArticle18234634672337097310.1007/s11845-013-0914-12-s2.0-84879555607N/AWOS:000320884900026Q4